June 12, 2015 — Fujifilm Medical Systems U.S.A. Inc. will demonstrate the latest generation of Synapse Cardiovascular version 6.0 at the American Society of Echocardiography (ASE) 26th Annual Scientific Sessions, June 13 – 15 in Boston. Synapse Cardiovascular version 6.0 is a total re-engineering of Fujifilm’s solution for echo reporting.

A first-in-human study shows how a powerful new drug finds and attaches itself to the ovarian and prostate cancer cells for both imaging and personalized cancer treatment. Study results were revealed at the 2015 annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).

Neuroinflammation caused by a reactive immune system could be tripping off the neurodegeneration seen in certain dementias, multiple sclerosis and other deadly diseases of the nervous system. A novel molecular imaging technique could be the key to understanding how best to treat these and other devastating diseases, according to a recent study presented at the 2015 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).

Siemens’ PETNET Solutions Inc. has entered into a nationwide agreement with U.K.-based Blue Earth Diagnostics Ltd. for the exclusive commercial manufacturing and distribution of Fluciclovine (18F), an investigational positron emission tomography and computed tomography (PET/CT) radiopharmaceutical. Fluciclovine (18F) is being studied for prostate imaging in clinical trials conducted in the United States, Japan, Italy, Norway, Sweden and Finland. The F-18-based radiopharmaceutical has a long half-life, which may facilitate its geographical distribution to clinical trial sites and then to clinical imaging centers once it gains approval from the U.S. Food and Drug Administration (FDA).

PET, PSMA, radiotracer, SNMMI 2015, prostate cancer

A new molecular imaging agent has been demonstrated to find prostate cancer that has spread to other tissues by locking in on the prostate specific membrane antigen (PSMA) enzyme, according to a new study. Results were presented at the 2015 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).

The latest advances in cardiovascular echocardiography will be presented at the 2015 American Society of Echocardiography (ASE) annual meeting June 12-16 in Boston. Several companies are making big announcements about new software and hardware.

non-Hodgkins lymphoma, PET/CT, recurrence, SNMMI 2015

Post-treatment surveillance with molecular imaging could mean the early start of a new, life-saving treatment for non-Hodgkin lymphoma (NHL), said researchers at the 2015 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).

Researchers announce the results of an early study that shows a fused fluoroscopic/ echocardiographic imaging (FFEI) system is feasible and provides improved guidance of interventional procedures in pediatric patients with congenital heart disease. An estimated 40,000 children are born in the United States each year with various forms of Congenital Heart Disease, with at least a quarter of those requiring some type of surgical intervention. The study is being presented at the 2015 American Society of Echocardiography (ASE) June 12- 16, in Boston.

 

Endovascular treatment (EVT) of intracranial aneurysm is effective in preventing long-term bleeding, but may be followed by aneurysm recurrences in a significant proportion of cases, according to a study published online in the journal Radiology.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now